Cargando…
Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 ad...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000540/ https://www.ncbi.nlm.nih.gov/pubmed/36899926 http://dx.doi.org/10.3390/cells12050789 |
_version_ | 1784903903181012992 |
---|---|
author | Tomela, Katarzyna Pietrzak, Bernadeta Galus, Łukasz Mackiewicz, Jacek Schmidt, Marcin Mackiewicz, Andrzej Adam Kaczmarek, Mariusz |
author_facet | Tomela, Katarzyna Pietrzak, Bernadeta Galus, Łukasz Mackiewicz, Jacek Schmidt, Marcin Mackiewicz, Andrzej Adam Kaczmarek, Mariusz |
author_sort | Tomela, Katarzyna |
collection | PubMed |
description | Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established. |
format | Online Article Text |
id | pubmed-10000540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100005402023-03-11 Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy Tomela, Katarzyna Pietrzak, Bernadeta Galus, Łukasz Mackiewicz, Jacek Schmidt, Marcin Mackiewicz, Andrzej Adam Kaczmarek, Mariusz Cells Article Myeloid-derived suppressor cells (MDSC) are a subset of immature myeloid cells with suppressive activity well described in the context of cancer. They inhibit anti-tumour immunity, promote metastasis formation and can lead to immune therapy resistance. In a retrospective study, blood probes of 46 advanced melanoma patients were analysed before the first administration of anti-PD-1 immunotherapy and in the third month of treatment for MDSC, immature monocytic (ImMC), monocytic MDSC (MoMDSC) and granulocytic MDSC (GrMDSC) by multi-channel flow cytometry. Cell frequencies were correlated with response to immunotherapy, progression-free survival (PFS) and lactate dehydrogenase (LDH) serum level. Responders to anti-PD-1 therapy had higher MoMDSC levels (4.1 ± 1.2%) compared to non-responders (3.0 ± 1.2%) (p = 0.0333) before the first administration of anti-PD-1. No significant changes in MDSCs frequencies were observed in the groups of patients before and in the third month of therapy. The cut-off values of MDSCs, MoMDSCs, GrMDSCs and ImMCs for favourable 2- and 3-year PFS were established. Elevated LDH level is a negative prognostic factor of response to the treatment and is related to an elevated ratio of GrMDSCs and ImMCs level compared to patients’ LDH level below the cut-off. Our data may provide a new perspective for more careful consideration of MDSCs, and specially MoMDSCs, as a tool for monitoring the immune status of melanoma patients. Changes in MDSC levels may have a potential prognostic value, however a correlation with other parameters must be established. MDPI 2023-03-02 /pmc/articles/PMC10000540/ /pubmed/36899926 http://dx.doi.org/10.3390/cells12050789 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tomela, Katarzyna Pietrzak, Bernadeta Galus, Łukasz Mackiewicz, Jacek Schmidt, Marcin Mackiewicz, Andrzej Adam Kaczmarek, Mariusz Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title | Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title_full | Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title_fullStr | Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title_full_unstemmed | Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title_short | Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy |
title_sort | myeloid-derived suppressor cells (mdsc) in melanoma patients treated with anti-pd-1 immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000540/ https://www.ncbi.nlm.nih.gov/pubmed/36899926 http://dx.doi.org/10.3390/cells12050789 |
work_keys_str_mv | AT tomelakatarzyna myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT pietrzakbernadeta myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT galusłukasz myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT mackiewiczjacek myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT schmidtmarcin myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT mackiewiczandrzejadam myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy AT kaczmarekmariusz myeloidderivedsuppressorcellsmdscinmelanomapatientstreatedwithantipd1immunotherapy |